FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1572113039> ?p ?o ?g. }

• W1572113039 abstract "Because of its potential of significantly increasing the rate of complete response (CR) up to the 30% range and prolonging the duration of event-free survival (EFS) and overall survival (OS) by approximately one year when compared with conventional chemotherapy, since the mid 1990s autologous stem-cell transplantation (ASCT) has been considered the standard of care for younger patients with newly diagnosed multiple myeloma (MM). More recently, introduction into the clinical practice of novel agents targeting the myeloma clone in its bone marrow microenvironment has changed the treatment paradigm for patients who are candidates for ASCT. In particular, recognition that thalidomide and bortezomib exibit remarkable activity in advanced refractory MM has stimulated their testing in different clinical scenarios, such as induction therapy in preparation for ASCT. Studies of thalidomide- dexamethasone (TD), eventually combined with a third drug such as doxorubicin (TAD) or cyclophosphamide (CTD), provided demonstration of increased rates of at least very good partial response (VGPR) with thalidomide- based regimens in comparison with traditional therapy given before ASCT. Since most of these studies were intended to explore pre-transplantation induction therapy, EFS and OS comparisons were frequently hampered. A large trial addressed this issue by randomizing patients to receive or not thalidomide upfront incorporated into melphalan- based double ASCT. In comparison with the no thalidomide arm of the study, addition of thalidomide to double ASCT significantly increased the CR rate, up to 62%, and prolonged EFS, whose 5-year estimate was 56%. After a median follow-up of 8 years, a survival advantage has recently become apparent among the one third of patients with metaphase cytogenetic abnormalities, a finding initially not reported. Similarly to thalidomide, also bortezomib has been incorporated into newer induction regimens in an attempt to increase the CR rate before ASCT and to ultimately improve post-autotransplantation outcome. Two large phase III studies conducted in France and Italy have explored the role of bortezomib- dexamethasone (VD) and VD combined with thalidomide (VTD) in comparison with VAD and TD, respectively, as induction therapy for younger patients who are candidates to receive ASCT. In both of them, VD and VTD were superior to the control group in terms of CR and ³VGPR, a finding confirmed also in high-risk patients carrying chromosome abnormalities. Importantly, high-quality responses effected by bortezomib-based regimens were furtherly increased following the first ASCT and resulted in significantly longer progression-free survival. Although data so far available suggest that novel agents and ASCT are complementary, a key issue is whether treatment with novel agents delays or eliminates the need for autotransplantation. Randomized clinical trials comparing these two approaches will definitely answer this unresolved question within the next few years." @default.
• W1572113039 created "2016-06-24" @default.
• W1572113039 creator A5030849615 @default.
• W1572113039 creator A5036642940 @default.
• W1572113039 creator A5040474758 @default.
• W1572113039 creator A5042253704 @default.
• W1572113039 creator A5044224344 @default.
• W1572113039 creator A5050631962 @default.
• W1572113039 creator A5051368482 @default.
• W1572113039 creator A5054934291 @default.
• W1572113039 creator A5055543156 @default.
• W1572113039 creator A5056548877 @default.
• W1572113039 creator A5071926851 @default.
• W1572113039 creator A5083765582 @default.
• W1572113039 creator A5085807104 @default.
• W1572113039 creator A5088055048 @default.
• W1572113039 date "2009-06-12" @default.
• W1572113039 modified "2023-09-26" @default.
• W1572113039 title "The road to cure in multiple myeloma: incorporation of novel agents into autologous stem cell transplantation" @default.
• W1572113039 doi "https://doi.org/10.4081/hmr.v3i3.558" @default.
• W1572113039 hasPublicationYear "2009" @default.
• W1572113039 type Work @default.
• W1572113039 sameAs 1572113039 @default.
• W1572113039 citedByCount "0" @default.
• W1572113039 crossrefType "journal-article" @default.
• W1572113039 hasAuthorship W1572113039A5030849615 @default.
• W1572113039 hasAuthorship W1572113039A5036642940 @default.
• W1572113039 hasAuthorship W1572113039A5040474758 @default.
• W1572113039 hasAuthorship W1572113039A5042253704 @default.
• W1572113039 hasAuthorship W1572113039A5044224344 @default.
• W1572113039 hasAuthorship W1572113039A5050631962 @default.
• W1572113039 hasAuthorship W1572113039A5051368482 @default.
• W1572113039 hasAuthorship W1572113039A5054934291 @default.
• W1572113039 hasAuthorship W1572113039A5055543156 @default.
• W1572113039 hasAuthorship W1572113039A5056548877 @default.
• W1572113039 hasAuthorship W1572113039A5071926851 @default.
• W1572113039 hasAuthorship W1572113039A5083765582 @default.
• W1572113039 hasAuthorship W1572113039A5085807104 @default.
• W1572113039 hasAuthorship W1572113039A5088055048 @default.
• W1572113039 hasConcept C121332964 @default.
• W1572113039 hasConcept C126322002 @default.
• W1572113039 hasConcept C141071460 @default.
• W1572113039 hasConcept C142424586 @default.
• W1572113039 hasConcept C143998085 @default.
• W1572113039 hasConcept C2776063141 @default.
• W1572113039 hasConcept C2776364478 @default.
• W1572113039 hasConcept C2776694085 @default.
• W1572113039 hasConcept C2776755627 @default.
• W1572113039 hasConcept C2777478702 @default.
• W1572113039 hasConcept C2778684742 @default.
• W1572113039 hasConcept C2779050716 @default.
• W1572113039 hasConcept C2779609412 @default.
• W1572113039 hasConcept C2780401358 @default.
• W1572113039 hasConcept C2911091166 @default.
• W1572113039 hasConcept C71924100 @default.
• W1572113039 hasConcept C87355193 @default.
• W1572113039 hasConceptScore W1572113039C121332964 @default.
• W1572113039 hasConceptScore W1572113039C126322002 @default.
• W1572113039 hasConceptScore W1572113039C141071460 @default.
• W1572113039 hasConceptScore W1572113039C142424586 @default.
• W1572113039 hasConceptScore W1572113039C143998085 @default.
• W1572113039 hasConceptScore W1572113039C2776063141 @default.
• W1572113039 hasConceptScore W1572113039C2776364478 @default.
• W1572113039 hasConceptScore W1572113039C2776694085 @default.
• W1572113039 hasConceptScore W1572113039C2776755627 @default.
• W1572113039 hasConceptScore W1572113039C2777478702 @default.
• W1572113039 hasConceptScore W1572113039C2778684742 @default.
• W1572113039 hasConceptScore W1572113039C2779050716 @default.
• W1572113039 hasConceptScore W1572113039C2779609412 @default.
• W1572113039 hasConceptScore W1572113039C2780401358 @default.
• W1572113039 hasConceptScore W1572113039C2911091166 @default.
• W1572113039 hasConceptScore W1572113039C71924100 @default.
• W1572113039 hasConceptScore W1572113039C87355193 @default.
• W1572113039 hasIssue "3" @default.
• W1572113039 hasLocation W15721130391 @default.
• W1572113039 hasOpenAccess W1572113039 @default.
• W1572113039 hasPrimaryLocation W15721130391 @default.
• W1572113039 hasRelatedWork W1966163309 @default.
• W1572113039 hasRelatedWork W1972302474 @default.
• W1572113039 hasRelatedWork W1974826126 @default.
• W1572113039 hasRelatedWork W2005208534 @default.
• W1572113039 hasRelatedWork W2012049438 @default.
• W1572113039 hasRelatedWork W2041519459 @default.
• W1572113039 hasRelatedWork W2072260210 @default.
• W1572113039 hasRelatedWork W2112499466 @default.
• W1572113039 hasRelatedWork W2116536558 @default.
• W1572113039 hasRelatedWork W2169175970 @default.
• W1572113039 hasRelatedWork W2312903969 @default.
• W1572113039 hasRelatedWork W2329368040 @default.
• W1572113039 hasRelatedWork W2483966113 @default.
• W1572113039 hasRelatedWork W2556759327 @default.
• W1572113039 hasRelatedWork W2563266914 @default.
• W1572113039 hasRelatedWork W2574360109 @default.
• W1572113039 hasRelatedWork W2589098986 @default.
• W1572113039 hasRelatedWork W2734518968 @default.
• W1572113039 hasRelatedWork W3029884595 @default.
• W1572113039 hasRelatedWork W3097831495 @default.
• W1572113039 hasVolume "3" @default.
• W1572113039 isParatext "false" @default.
• W1572113039 isRetracted "false" @default.

• next